Work

Abstract PR05: In vivo antitumor activity of the PARP inhibitor niraparib (MK-4827) in homologous recombination deficient and proficient ovarian cancer

Year: 2013

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ovca13-pr05

Authors: Mariam Al Hilli, S. John Weroha, Marc Becker, Xiaonan Hou, Sean Harrington, Sarah McKinstrey, Kimberly Kalli, Karin Goodman, Keith Wilcoxen, Elizabeth Swisher, Scott Kaufmann, Paul Haluska

Institutions: Mayo Clinic, Tesaro (United States), University of Washington

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2094049066

Cites:

Cited by: 1

Related to: 10